Clinical Trial Update: Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating an EGFR-targeted therapy in patients with advanced ovarian, primary peritoneal, and fallopian tube cancers; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ovarian Cancer, Peritoneal Neoplasms | Phase 2 | Status: COMPLETED